Ormat Technologies offers a strong investment opportunity through its reliable renewable power business. The company benefits from contract repricing and ongoing developments, which are expected to drive earnings growth before new geothermal technologies scale. Forecasts project revenues of $1.35 billion and adjusted EBITDA of $780 million by 2028, supporting a Buy rating with a target share price of $120, implying a 26% upside. However, risks such as project delays, drilling challenges, market volatility, and capital needs remain and must be managed carefully.
Ormat Technologies and its growth outlook are noted here with Pluang's Utilities sector data as of Sep 14, 2026 19:01 WIB. For readers following Utilities, 12 of 23 priced US stocks rose and 7 fell today. Notable movers include LNG (Cheniere Energy) at USD 283.00 with a 1-day change of +1.67%, TDW (Tidewater Inc) at USD 93.50 with +0.57%, and AWK (American Water Works Company Inc) at USD 138.33 with +0.46%.
The CHMP of the European Medicines Agency has recommended approval for Johnson & Johnson's TALVEY (talquetamab) combined with daratumumab, with or without pomalidomide, for treating adults with relapsed or refractory multiple myeloma who have had at ...
The European Medicines Agency's CHMP has recommended approving Johnson & Johnson's TALVEY® (talquetamab) combined with daratumumab for treating relapsed or refractory multiple myeloma earlier in the treatment process, starting from the second line. T...
The European Medicines Agency's CHMP has recommended approval for Johnson & Johnson's TALVEY® (talquetamab) in combination with daratumumab for treating relapsed or refractory multiple myeloma (RRMM) in patients who have had at least one prior therap...
Fortrea Holdings and Omico have formed a partnership to enhance precision oncology research in Australia by linking cancer patients to biomarker-matched clinical trials. This collaboration combines Fortrea's oncology trial expertise with Omico's Prec...
Fortrea Holdings and Omico have formed a partnership to accelerate precision oncology research in Australia by combining Fortrea's clinical trial expertise with Omico's Precision Oncology Screening Platform (PrOSPeCT). This collaboration aims to impr...
